# Effects and interactive effects of high-altitude environment on metabolism in normal and diabetic populations: a comparative metabolomics study

**Authors:** Jing Shi, Jinli Meng, Chenghui Zhang, Li Feng, Suyuan Wang, Hengyan Li, Yongyue Guo, Xin Hu, Xiaomei Li, Wanlin He, Jian Cheng, Yunhong Wu

PMC · DOI: 10.3389/fendo.2026.1736270 · Frontiers in Endocrinology · 2026-02-12

## TL;DR

This study compares how high-altitude living affects metabolism in people with and without diabetes, identifying specific biomarkers that could help diagnose diabetes in high-altitude regions.

## Contribution

The study identifies altitude-specific metabolic biomarkers for T2DM, particularly highlighting guanosine as a robust and unique indicator.

## Key findings

- 26 differentially abundant metabolites were found in high-altitude T2DM patients compared to other groups.
- Pipecolic acid, lauric acid, guanosine, and kaempferol were identified as potential early biomarkers for high-altitude diabetes.
- Guanosine was confirmed as the most robust and altitude-specific biomarker for T2DM through multicenter validation.

## Abstract

High-altitude environments impose unique physiological stresses that may alter metabolic dysregulation in individuals with type 2 diabetes mellitus (T2DM). However, the key determinants driving altitude-specific metabolic differences in diabetic patients remain insufficiently characterized. This study aimed to identify critical metabolic biomarkers and pathways distinguishing T2DM patients residing at high versus low altitudes.

Serum samples were collected from 100 participants stratified into four matched groups: high-altitude T2DM (H_T2DM), high-altitude healthy controls (H_HC), low-altitude T2DM (L_T2DM), and low-altitude healthy controls (L_HC). Metabolomic profiling was performed using ultra-performance liquid chromatography‒quadrupole time-of-flight mass spectrometry (UPLC‒Q‒TOF‒MS) to compare endogenous metabolite abundance across groups. Pathway topology analysis was conducted to annotate functional metabolic pathways, and multicenter validation was implemented to verify the robustness of candidate biomarkers.

A total of 26 differentially abundant endogenous metabolites were identified in H_T2DM patients relative to the other three groups, with 18 metabolites significantly upregulated and 8 downregulated. Pipecolic acid, lauric acid, guanosine, and kaempferol were identified as potential early biomarkers for high-altitude diabetes, collectively achieving a prediction accuracy of 92%. These biomarkers were linked to core metabolic pathways including lysine degradation, fatty acid biosynthesis, and purine metabolism. Multicenter validation further confirmed guanosine as the most robust and altitude-specific biomarker for T2DM.

Our comprehensive metabolomic analysis reveals distinct metabolic perturbations in T2DM patients under high-altitude conditions, highlighting guanosine as a unique biomarker for identifying altitude-related diabetic metabolic dysregulation. These findings advance our understanding of the pathophysiological mechanisms underlying T2DM in high-altitude environments and provide a potential diagnostic target for clinical management of diabetic populations in such regions.

## Linked entities

- **Chemicals:** pipecolic acid (PubChem CID 849), lauric acid (PubChem CID 3893), guanosine (PubChem CID 135398635), kaempferol (PubChem CID 5280863)
- **Diseases:** type 2 diabetes mellitus (MONDO:0005148), T2DM (MONDO:0005148)

## Full-text entities

- **Genes:** SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, GCLC (glutamate-cysteine ligase catalytic subunit) [NCBI Gene 2729] {aka CNSHA7, GCL, GCS, GLCL, GLCLC}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, LDHA (lactate dehydrogenase A) [NCBI Gene 3939] {aka GSD11, HEL-S-133P, LDHM, PIG19}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** T2DM (MESH:D003924), heart failure (MESH:D006333), DMs (MESH:D012734), Liver damage (MESH:D056486), diabetic ketosis (MESH:D016883), H (MESH:D000848), diabetic foot ulcers (MESH:D017719), diabetes complications (MESH:D048909), hyperglycemic (MESH:D006944), cardiovascular diseases (MESH:D002318), diabetic retinopathy (MESH:D003930), insulin resistance (MESH:D007333), hypoxic (MESH:D002534), metabolic disease (MESH:D008659), Hypoxia (MESH:D000860), HL (MESH:C538324), cirrhosis (MESH:D005355), cancer (MESH:D009369), DM (MESH:D003920), chronic kidney disease (MESH:D051436)
- **Chemicals:** glutathione (MESH:D005978), lipid (MESH:D008055), palmitic acid (MESH:D019308), purine (MESH:C030985), oleic acid (MESH:D019301), lysine (MESH:D008239), Guanosine (MESH:D006151), creatinine (MESH:D003404), purine nucleoside (MESH:D011684), glucose (MESH:D005947), N'1-(2-chlorobenzoyl)-2-[(2-methyl-1H-indol-3-yl)thio]ethanohydrazide (-), TG (MESH:D013866), 2-hydroxy-6-aminopurine (MESH:C008183), carbohydrates (MESH:D002241), fatty acid (MESH:D005227), Pipecolic acid (MESH:C031345), water (MESH:D014867), kaempferol (MESH:C006552), nitrogenous base (MESH:D009711), free fatty acids (MESH:D005230), lauric acid (MESH:C030358), cholesterol (MESH:D002784), 8-OHdG (MESH:D000080242), blood glucose (MESH:D001786), adenosine (MESH:D000241), succinic acid (MESH:D019802), inosine (MESH:D007288), methanol (MESH:D000432), linoleic acid (MESH:D019787), TC (MESH:D013667), oxygen (MESH:D010100), lactic acid (MESH:D019344), isoleucine (MESH:D007532), uric acid (MESH:D014527), triglycerides (MESH:D014280)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12935616/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12935616/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC12935616/full.md

---
Source: https://tomesphere.com/paper/PMC12935616